A Comprehensive In Vitro and In Silico Approach for Targeting 4-Hydroxyphenyl Pyruvate Dioxygenase: Towards New Therapeutics for Alkaptonuria
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26073181 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Giulia Bernardini und 8 weiteren Autor:innen. Beteiligte Einrichtung: ONE-HEALTH Lab, Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro, 53100 Siena, Italy. Hauptthemen laut MEDLINE: Alkaptonuria, 4-Hydroxyphenylpyruvate Dioxygenase, Enzyme Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dello Sviluppo Economico (MISE), POC MISE ARNO 2020—POCARNO.
Abstract (Originalsprache)
Alkaptonuria (AKU) is an ultra-rare genetic disorder caused by mutations in the homogentisate 1,2-dioxygenase (HGD) gene, leading to the accumulation of homogentisic acid (HGA). Current treatment options are limited, with Nitisinone (Orfadin or NTBC) being the only approved drug. However, its long-term use raises concerns due to significant adverse effects, highlighting the urgent need for safer alternatives. AKU manifests with progressive and often painful symptoms, severely impacting patients’ quality of life. Identifying new therapeutic approaches to inhibit 4-hydroxyphenyl pyruvate dioxygenase (4-HPPD) is critical to improving outcomes for AKU patients. In this study, we present a novel integrated in vitro and in silico strategy to assess the residence time of 4-HPPD inhibitors. In particular, we evaluated several features of a set of triketone compounds including their inhibitory efficacy, residence time, and ochronotic pigment accumulation. By means of our integrated approach, we investigated the pharmacokinetic and pharmacodynamics properties of novel 4-HPPD inhibitors and provided a promising foundation for the development of safer and more effective treatments for AKU.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ONE-HEALTH Lab, Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro, 53100 Siena, Italy.
- MetabERN, Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro, 53100 Siena, Italy.
ORCID-Profile: Giulia Bernardini, Elena Petricci, Giulia Romagnoli, Demetra Zambardino, Fabrizio Manetti, Daniela Braconi, Michela Geminiani, Annalisa Santucci
Förderung
- Ministero dello Sviluppo Economico (MISE)
- POC MISE ARNO 2020—POCARNO
Zitieren
APA
Bernardini, G., Trezza, A., Petricci, E., Romagnoli, G., Zambardino, D., Manetti, F., Braconi, D., Geminiani, M., & Santucci, A. (2025). A Comprehensive In Vitro and In Silico Approach for Targeting 4-Hydroxyphenyl Pyruvate Dioxygenase: Towards New Therapeutics for Alkaptonuria. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26073181
Vancouver
Bernardini G, Trezza A, Petricci E, Romagnoli G, Zambardino D, Manetti F, et al. A Comprehensive In Vitro and In Silico Approach for Targeting 4-Hydroxyphenyl Pyruvate Dioxygenase: Towards New Therapeutics for Alkaptonuria. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26073181
BibTeX
@article{Bernardini2025,
author = {Bernardini, Giulia and Trezza, Alfonso and Petricci, Elena and Romagnoli, Giulia and Zambardino, Demetra and Manetti, Fabrizio and Braconi, Daniela and Geminiani, Michela and Santucci, Annalisa},
title = {A Comprehensive In Vitro and In Silico Approach for Targeting 4-Hydroxyphenyl Pyruvate Dioxygenase: Towards New Therapeutics for Alkaptonuria},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26073181}
}
EUVIMED